$PETV

PetVivo Holdings, Inc. (PETV): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

PetVivo Holdings, Inc. (PETV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 5151 Edina Industrial Blvd., Suite 575, Minneapolis, MN 55439 | (952) 405-6216 | www.petvivo.com PRESS RELEASE: Jaime Pickett Joins PetVivo Holdings, Inc. Board of Directors MINNEAPOLIS, MN, US, September 22, 2026 — PetVivo Holdings, Inc. (OTCQX: PETV) (the “Company”

Original reporting
Published Sep 22, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 11:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PETV
Neutral
medium confidence
Mentioned
$PETV
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PETVNeutralLow
01

Why it matters

The board appointment is a standard corporate governance update with limited immediate financial impact.

02

Market read

Minor relevance; primarily of interest to existing shareholders and sector specialists.

03

What to watch

Dr. Pickett's extensive veterinary network could unlock new partnership opportunities not yet reflected in the stock.

Relevance 6/10Novelty 4/10Timing: effective September 22, 2026

Background

PetVivo Holdings, Inc. (OTCQX: PETV) is an emerging biomedical device company targeting companion‑animal health.

Company-level read

Ticker impact

$PETVNeutralMedium confidence
Context

PetVivo announced the appointment of Dr. Jaime K. Pickett to its Board of Directors, effective September 22, 2026.

Expected impact

minimal short‑term movement; potential modest upside if market views governance strengthening positively.

Evidence & confidence

Director appointments are routine corporate actions for micro‑caps; no material financial terms disclosed.

Market effects

May signal continued focus on veterinary‑tech sector but no broader industry shift.

Limited to US OTC market; negligible regional effect.

None

Counterpoint

Investors could view the appointment as a distraction if the board change signals internal challenges.

Key entities

  • PetVivo Holdings, Inc.

    OTCQX‑listed biomedical device firm for animal health.

  • Dr. Jaime K. Pickett

    Veterinary executive appointed to the board.

Related articles

$PETVMedAI 8/10

PetVivo Holdings Announces Transformative Acquisition Of PiezoBioMembrane To Build a Leading Functional Biomaterials Platform

PetVivo Holdings (OTCQX: PETV) said it agreed to acquire PiezoBioMembrane (PBM) via a merger, with PBM becoming a wholly owned subsidiary of Cosmeta Corp. PetVivo will issue 3,000,000 shares to PBM shareholders, with some consideration tied to milestones. The company expects PBM’s functional biomaterials and piezoelectric tech to expand IP and product development; closing is subject to customary conditions.

$XRPNMedAI 8/10

Ripple-Backed Evernorth Eyes $132M Funding Amid XRP Buying Plans

Evernorth Holdings (XRPN) plans to raise up to $132.2M by exercising public warrants at $11.50 per share. The company intends to use proceeds to buy XRP, though warrant holders may not exercise. Evernorth aims to grow its XRP holdings per share, with existing cash and XRP contributions totaling $300M and 473M XRP. Warrant exercises could dilute shares.

$RCUSHigh

Arcus Biosciences stock falls on public offering announcement

Arcus Biosciences (NYSE:RCUS) shares fell 6.6% in after-hours trading after announcing a public offering of common stock. The company plans to sell shares, with underwriters having a 30-day option for additional shares. Shares had already dropped 20% during regular trading. Citi analyst Yigal Nochomovitz maintained a Buy rating and $50.00 price target, noting clinical trial results met market expectations.